Table 3.
Cox proportional hazards regression analysis for factors associated with prognosis of patients treated with lenvatinib
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age | 1.03 | 0.989–1.082 | 0.139 | |||
| Gender male | 0.901 | 0.268–3.036 | 0.867 | |||
| Child Pugh ≥ 7 (B) | 5.507 | 1.598–18.97 | 0.00687 | 2.348 | 0.644–8.559 | 0.196 |
| MVI | 2.815 | 1.276–6.207 | 0.0103 | 1.984 | 0.878–4.482 | 0.995 |
| EHS | 0.947 | 0.429–2.088 | 0.892 | |||
| AFP > 200 | 2.736 | 1.219–6.14 | 0.0147 | 2.388 | 0.997–5.720 | 0.0508 |
| Past history of TKI | 1.137 | 0.499–2.586 | 0.76 | |||
| RECIST best (OR/SD/PD) | 0.377 | 0.201–0.708 | 0.0024 | 0.259 | 0.0723–0.928 | 0.038 |
| mRECIST best (OR/SD/PD) | 0.581 | 0.344–0.981 | 0.0422 | 0.0646 | 0.00282–1.481 | 0.863 |
| Choi best (OR/SD/PD) | 0.482 | 0.293–0.792 | 0.00395 | 0.0893 | 0.00343–2.323 | 0.146 |
Boldface means P value are <0.05.
AFP, alpha‐fetoprotein; EHS, extrahepatic spread; HR, hazards ratios; MVI, major vascular invasion; OR, objective response; PD, progressive disease; SD, stable disease; TKI, tyrosine kinase inhibitor.